Comparison of hepatitis B surface antibody decay rates after vaccination between hemodialysis and peritoneal dialysis patients.

[Guest guest]

Vaccine. 2011 Mar 30. [Epub ahead of print]

Comparison of hepatitis B surface antibody decay rates after vaccination between

hemodialysis and peritoneal dialysis patients.

Lin SY, Liu JH, Lin CC, Wang SM, Tsai CA, Chou CY, Kuo HL, Wang IK, Liu YL, Lin

HH, Huang CC.

China Medical University Hospital, Division of Nephrology, Department of

Internal Medicine, Taichung, Taiwan, ROC.

Abstract

BACKGROUND AND OBJECTIVES: The available information about maintaining effective

immunity after hepatitis B virus (HBV) vaccination in dialysis patients is

limited. The aim of this study was to determine whether a difference exists in

the persistence of immunity between hemodialysis (HD) and peritoneal dialysis

(PD) patients. We compared the decay rate of hepatitis B surface antibody

(anti-HBs) titers after HBV vaccination between HD and PD patients. DESIGN,

SETTING, PARTICIPANTS, AND

MEASURES: A total of 103 HD and 53 PD patients who were completely vaccinated

were enrolled. We examined their anti-HBs titers at the 1st month after

vaccination then annually thereafter. Changes in the anti-HBs titers were

assessed by comparing annual geometric mean titers (GMTs).

RESULTS: The slopes of the anti-HBs titer decay rates plotted on a logarithmic

scale for the HD and PD groups were -23.41 and -31.48, respectively. The decay

rate of the PD group was significantly faster than that of the HD group

(P=0.0053).

CONCLUSION: The decay rate of anti-HBs titers in the PD group was faster than

that in the HD group. Hepatitis B vaccination could not offer long-term

protection in HD or PD patients. Post-vaccination testing every 6-12 months is

necessary and revaccination may be protective in dialysis patients, especially

in hyper-endemic areas of hepatitis B infection.

Copyright © 2011. Published by Elsevier Ltd.

PMID: 21458609 [PubMed - as supplied by publisher]